Tysabri-associated PML Incidence

3.50

3.00
PML Incidence per 1000 patients

2.50

2.00

1.50

1.00

0.50

0.00

Clinical Trials All Post Marketing Patients Patients Treated ≥ 12 Infusions Patients Treated ≥ 18 Infusions
Patient Uptake as of: 28-Oct-09 30-Nov-09 31-Dec-09 31-Jan-10 28-Feb-10 31-Mar-10 30-Apr-10 28-Oct-09 30-Nov-09 31-Dec-09 31-Jan-10 28-Feb-10 31-Mar-10 30-Apr-10 28-Oct-09 30-Nov-09 31-Dec-09 31-Jan-10 28-Feb-10 31-Mar-10 30-Apr-10
High 2.80 0.57 0.63 0.67 0.73 0.83 0.89 0.92 1.01 1.09 1.15 1.23 1.39 1.47 1.51 1.23 1.29 1.31 1.42 1.63 1.72 1.77
Mid 1.00 0.38 0.43 0.47 0.52 0.62 0.67 0.70 0.68 0.76 0.81 0.89 1.03 1.10 1.14 0.79 0.86 0.89 1.00 1.18 1.27 1.32
Low 0.20 0.25 0.29 0.32 0.36 0.44 0.49 0.52 0.43 0.50 0.55 0.62 0.74 0.81 0.84 0.47 0.54 0.58 0.67 0.83 0.91 0.96

PML Cases 24 28 31 35 42 46 49
as of 28-Oct-09 30-Nov-09 12-Jan-09 9-Feb-10 10-Mar-10 6-Apr-10 6-May-10

Estimated Patients in Treatment Cohort*: 37,567 38,644 39,700 40,830 41,960 43,100 44,240 26,667 28,451 30,200 31,330 32,460 33,600 34,740
Estimated PML Cases in Treatment Cohort: 24 28 31 35 42 46 49 21 24 27 31 38 43 46

* Interpolated from quarterly data provided by Biogen Idec.

ce by Treatment Duration Cohort

Patients Treated ≥ 24 Infusions Patients Treated ≥ 30 Infusions Patients Treated ≥ 36 Infusions

28-Oct-09 30-Nov-09 31-Dec-09 31-Jan-10 28-Feb-10 31-Mar-10 30-Apr-10 28-Oct-09 30-Nov-09 31-Dec-09 31-Jan-10 28-Feb-10 31-Mar-10 30-Apr-10 28-Oct-09 30-Nov-09 31-Dec-09 31-Jan-10 28-Feb-10 31-Mar-10 30-Apr-10
1.98 1.96 1.93 1.91 2.19 2.21 2.22 2.65 1.99 1.88 1.92 2.28 2.37 2.24 3.14 2.28 1.79 1.81 1.80 2.04 1.78
1.26 1.28 1.29 1.29 1.55 1.59 1.62 1.44 1.05 1.02 1.10 1.42 1.53 1.47 0.87 0.63 0.50 0.62 0.70 0.94 0.82
0.75 0.79 0.82 0.84 1.06 1.11 1.14 0.69 0.48 0.49 0.57 0.83 0.94 0.91 0.11 0.08 0.06 0.13 0.19 0.34 0.30

16,233 17,479 18,700 20,100 21,500 22,900 24,300 8,667 9,643 10,600 11,630 12,660 13,700 14,740 4,053 4,410 4,760 5,440 6,120 6,800 7,480
20 22 24 26 33 36 39 12 10 11 13 18 21 22 3 3 2 3 4 6 6

Note: Due to limited data, these estimated PML case numbers are less accurate.